Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jazz PharmaceuticalsJAZZ +2.21%73 Return-on-Tangible-Equity is Negative Tangible Equity% as of Mar. 2026. GuruFocus rates JAZZ with a GF Score™ of 73/100 and a GF Value™ of $150.67 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,199 Biotechnology companies, Jazz Pharmaceuticals ranks better than 99.92% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Jazz Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2026 was $1,172 Mil. Jazz Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $-1,708 Mil. Therefore, Jazz Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was Negative Tangible Equity%.
The historical rank and industry rank for Jazz Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
JAZZ'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 186.14 Med: 186.14 Max: 186.14
Current: Negative Tangible Equity
During the past 13 years, Jazz Pharmaceuticals's highest Return-on-Tangible-Equity was 186.14%. The lowest was 186.14%. And the median was 186.14%.
JAZZ's Return-on-Tangible-Equity is ranked better than 99.92% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs JAZZ: Negative Tangible Equity
Jazz Pharmaceuticals (NAS:JAZZ) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Jazz Pharmaceuticals Return-on-Tangible-Equity Related Terms
Jazz Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals Return-on-Tangible-Equity Chart
JAZZ vs BBIO, EXEL, IONS: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of Negative Tangible Equity% mean?
Jazz Pharmaceuticals (JAZZ) has a Return-on-Tangible-Equity of Negative Tangible Equity% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jazz Pharmaceuticals and its competitors. Over the past decade, Jazz Pharmaceuticals' Return-on-Tangible-Equity has ranged from 186.14 to 186.14. According to the industry distribution chart, Jazz Pharmaceuticals ranks #1 out of 1199 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Jazz Pharmaceuticals' Return-on-Tangible-Equity too high?
Jazz Pharmaceuticals' current Return-on-Tangible-Equity is Negative Tangible Equity%. Over the past 10 years, this metric has ranged from a low of 186.14 to a high of 186.14. Based on the distribution chart, Jazz Pharmaceuticals ranks #1 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Return-on-Tangible-Equity compare to BBIO and EXEL?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #1 out of 1199 companies for Return-on-Tangible-Equity. This places Jazz Pharmaceuticals in the top 0% of its industry — outperforming the majority of peers. Historically, Jazz Pharmaceuticals' own Return-on-Tangible-Equity has ranged from 186.14 to 186.14 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Return-on-Tangible-Equity is Negative Tangible Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (JAZZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $150.67, compared to a current price of $247.53 — trading 64.3% above its estimated fair value. The current Return-on-Tangible-Equity is Negative Tangible Equity%. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Jazz Pharmaceuticals (JAZZ), the current Return-on-Tangible-Equity is Negative Tangible Equity% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (JAZZ) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of $247.53 is trading 64.3% above its estimated GF Value™ of $150.67.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
No single metric tells the full story. See the JAZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score
Get the complete analysis for JAZZ
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAZZ has been successfully added to your 
